CHICAGO - Tempus AI, Inc. (NASDAQ: TEM), a healthcare AI company with a market capitalization of $5.5 billion and impressive revenue growth of 32% over the last twelve months, has announced the national launch of its new personal health concierge app, olivia. According to InvestingPro analysis, while the company maintains strong liquidity with a current ratio of 2.69, it operates with moderate debt levels as it pursues growth opportunities. The app aims to centralize patient health data and provide actionable AI-driven insights, marking a significant step in advancing precision medicine and enhancing patient care.
olivia is designed to allow patients to aggregate their health information from over 1,000 health systems and various health devices into one platform. The app organizes this data into a dynamic timeline, providing access to records such as lab results and imaging reports. It also enables patients to share their data, including DICOM images, with their care teams.
The app's AI capabilities offer features like a Smart Profile Summary that synthesizes patient data into a comprehensive profile and an AI-enabled Notetaker for summarizing physician appointments. olivia also facilitates health monitoring by allowing patients to track various health metrics and sync data from Apple (NASDAQ:AAPL) Health and Google (NASDAQ:GOOGL) Fit.
Eric Lefkofsky, Founder and CEO of Tempus, expressed that the company's goal has always been to improve patient outcomes by utilizing data and AI. He emphasized that tools like olivia are becoming indispensable for patients to understand and manage their healthcare journey. The company's recent performance has been noteworthy, with InvestingPro data showing a 10.43% stock price increase over the past week, though analysts anticipate continued profitability challenges in the near term.
The olivia app is now available for download on both iOS and Android platforms. This development reflects Tempus's commitment to providing AI-enabled precision medicine solutions to physicians and patients, contributing to personalized patient care and the development of optimal therapeutics.
Tempus, known for one of the world's largest libraries of multimodal data and an operating system to make that data useful, continues to focus on enhancing patient care through technology. The company's approach is to learn from the treatment of previous patients to benefit current and future patients.
The information in this article is based on a press release statement from Tempus AI, Inc. InvestingPro analysis suggests the stock may be undervalued at current levels, with additional insights available through their comprehensive financial analysis tools. Subscribers gain access to over 10 additional ProTips and detailed metrics to make informed investment decisions.
In other recent news, Tempus AI announced the national launch of its AI-enabled personal health concierge app, Olivia. The company also reported preliminary fourth-quarter 2024 total revenues of approximately $200 million, reflecting an estimated 35% growth. However, this figure fell short of analyst expectations, prompting Loop Capital to trim its price target on Tempus AI from $57.00 to $52.00, while maintaining a Buy rating.
Simultaneously, Tempus AI unveiled a whole-genome sequencing test, named xH, aimed at enhancing personalized treatment for hematological cancer patients. The test is currently available for research purposes only, with clinical availability expected within the next year.
Furthermore, Tempus AI reported a 30% annual revenue growth in 2024, with a total revenue of approximately $693 million. In the fourth quarter alone, the company saw revenues of about $200 million, a 35% rise year-over-year.
Piper Sandler raised the price target for Tempus AI from $40 to $70, maintaining a neutral rating. However, Stifel downgraded Tempus AI's stock from Buy to Hold but increased the price target to $65. These adjustments followed Tempus AI's recent earnings report and are among the recent developments for the company.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.